Literature DB >> 24366347

From molecular understanding to clinical advances.

Chung-Han Lee1, Robert J Motzer1.   

Abstract

Big data and computational biology brought to the forefront a number of potential actionable mutations and drug targets in clear cell renal cell carcinoma in 2013. As we continue to unravel the molecular underpinnings of tumorigenesis and progression, the clinical benefits will eventually be reaped.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24366347     DOI： 10.1038/nrurol.2013.307

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


  7 in total

Review 1.  The genetic basis of kidney cancer: a metabolic disease.

Authors:  W Marston Linehan; Ramaprasad Srinivasan; Laura S Schmidt
Journal:  Nat Rev Urol       Date:  2010-05       Impact factor: 14.432

2.  In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation.

Authors:  Paulo A Gameiro; Juanjuan Yang; Ana M Metelo; Rocio Pérez-Carro; Rania Baker; Zongwei Wang; Alexandra Arreola; W Kimryn Rathmell; Aria Olumi; Pilar López-Larrubia; Gregory Stephanopoulos; Othon Iliopoulos
Journal:  Cell Metab       Date:  2013-03-05       Impact factor: 27.287

3.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; David Cella; James Reeves; Robert Hawkins; Jun Guo; Paul Nathan; Michael Staehler; Paul de Souza; Jaime R Merchan; Ekaterini Boleti; Kate Fife; Jie Jin; Robert Jones; Hirotsugu Uemura; Ugo De Giorgi; Ulrika Harmenberg; Jinwan Wang; Cora N Sternberg; Keith Deen; Lauren McCann; Michelle D Hackshaw; Rocco Crescenzo; Lini N Pandite; Toni K Choueiri
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

4.  Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability.

Authors:  David R Wise; Patrick S Ward; Jessica E S Shay; Justin R Cross; Joshua J Gruber; Uma M Sachdeva; Jesse M Platt; Raymond G DeMatteo; M Celeste Simon; Craig B Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-21       Impact factor: 12.779

5.  Comprehensive molecular characterization of clear cell renal cell carcinoma.

Authors: 
Journal:  Nature       Date:  2013-06-23       Impact factor: 49.962

6.  Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.

Authors:  R Kumar; M-C Crouthamel; D H Rominger; R R Gontarek; P J Tummino; R A Levin; A G King
Journal:  Br J Cancer       Date:  2009-10-20       Impact factor: 7.640

7.  Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.

Authors:  Sakari Vanharanta; Weiping Shu; Fabienne Brenet; A Ari Hakimi; Adriana Heguy; Agnes Viale; Victor E Reuter; James J-D Hsieh; Joseph M Scandura; Joan Massagué
Journal:  Nat Med       Date:  2012-12-09       Impact factor: 53.440
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.